神经内分泌肿瘤肝转移的肝移植治疗
Liver transplantation for neuroendocrine tumour liver metastases.
作者信息
Fan Sheung Tat, Le Treut Yves Patrice, Mazzaferro Vincenzo, Burroughs Andrew K, Olausson Michael, Breitenstein Stefan, Frilling Andrea
机构信息
Department of Surgery, The University of Hong Kong, and Liver Surgery Centre, Hong Kong Sanatorium and Hospital, Hong Kong.
出版信息
HPB (Oxford). 2015 Jan;17(1):23-8. doi: 10.1111/hpb.12308. Epub 2014 Jul 3.
OBJECTIVE
Search and review of available literature were made to define the indications for and timing of liver transplantation for neuroendocrine tumour (NET) liver metastases.
METHODS
Electronic bibliographical databases were searched. Prospective and retrospective cohort studies and case-controlled studies were used for qualitative and quantitative synthesis of the systematic review. Reports of patients with liver transplantation alone for NET liver metastases of any origin or combined with resection of extrahepatic tumour deposits were recruited.
RESULTS
The number of patients who have undergone liver transplantation for NET liver metastases is 706. The post-transplant 5-year survival rate from the time of diagnosis was approximately 70%. NET patients with metastases confined to the liver and not poorly differentiated are favourable candidates for liver transplantation. Selection of patients based on evolution of tumours over 6 months is not recommended.
CONCLUSION
Non-resectable NET liver metastasis resistant to medical treatment and confined to the liver is an accepted indication for liver transplantation.
目的
检索并综述现有文献，以明确神经内分泌肿瘤（NET）肝转移患者肝移植的指征及时机。
方法
检索电子文献数据库。前瞻性和回顾性队列研究以及病例对照研究用于本系统综述的定性和定量分析。纳入了仅因任何来源的NET肝转移或合并肝外肿瘤病灶切除而接受肝移植患者的报告。
结果
因NET肝转移接受肝移植的患者有706例。诊断后移植后5年生存率约为70%。转移局限于肝脏且分化程度不差的NET患者是肝移植的合适人选。不建议根据肿瘤6个月的进展情况来选择患者。
结论
无法切除且对药物治疗耐药、局限于肝脏的NET肝转移是肝移植公认的指征。
Zotero 插件